telotristat etiprate + octreotide LAR depot

This is a combination drug regimen comprising **telotristat etiprate**, an oral small molecule inhibitor of peripheral serotonin synthesis (tryptophan hydroxylase inhibitor), and **octreotide LAR depot**, an injectable long-acting release somatostatin analogue. Telotristat etiprate lowers production of serotonin by neuroendocrine tumors, thereby reducing serotonin-mediated diarrhea in carcinoid syndrome patients whose symptoms are inadequately controlled by octreotide alone[1][2][5][6][7]. Octreotide LAR depot acts on somatostatin receptors, providing antisecretory and anti-tumor effects. The regimen is indicated for **carcinoid syndrome diarrhea** in adults who are not adequately controlled by somatostatin analog therapy alone.

Other names

telotristat etiprate + octreotide LAR depottelotristat ethyl + octreotide LAR depot